Pfizer (PFE) Receivables - Net (2016 - 2025)
Historic Receivables - Net for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $14.3 billion.
- Pfizer's Receivables - Net fell 132.17% to $14.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 billion, marking a year-over-year decrease of 132.17%. This contributed to the annual value of $11.5 billion for FY2024, which is 89.05% down from last year.
- Per Pfizer's latest filing, its Receivables - Net stood at $14.3 billion for Q3 2025, which was down 132.17% from $12.1 billion recorded in Q2 2025.
- Pfizer's 5-year Receivables - Net high stood at $16.1 billion for Q4 2022, and its period low was $9.9 billion during Q2 2021.
- Its 5-year average for Receivables - Net is $12.2 billion, with a median of $11.6 billion in 2023.
- Its Receivables - Net has fluctuated over the past 5 years, first skyrocketed by 4506.51% in 2021, then tumbled by 3249.09% in 2023.
- Pfizer's Receivables - Net (Quarter) stood at $11.5 billion in 2021, then dropped by 4.59% to $11.0 billion in 2022, then increased by 5.61% to $11.6 billion in 2023, then fell by 0.89% to $11.5 billion in 2024, then grew by 24.4% to $14.3 billion in 2025.
- Its Receivables - Net was $14.3 billion in Q3 2025, compared to $12.1 billion in Q2 2025 and $11.8 billion in Q1 2025.